Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ambroxol hydrochloride inhalation solution in adult lower respiratory tract infection with viscous sputum
CTR20180113Phase 3Active
- Sponsor
- Wanbangde Pharmaceutical Holding Group
- Start
- Feb 2018
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of ambroxol in pulmonary infection, acute bronchitis, chronic bronchitis (CB), pneumonia, chronic obstructive pulmonary disease (COPD), sponsored by Wanbangde Pharmaceutical Holding Group. Started Feb 2018; status: active.
02
Drugs
ambroxol
03
Conditions
pulmonary infectionacute bronchitischronic bronchitis (CB)pneumoniachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on CTR20180113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20180113.